Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

In-process research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Moderna

Novavax

Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.

Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising

Sharp up-and-down moves in OCGN stock shouldn't scare investors away, as a regulator's nod for Covaxin should put the stock back on track. The post WHO Approval Should Get Ocugen Stock Over the $15 Barrier appeared first on InvestorPlace.

WHO Approval Should Get Ocugen Stock Over the $15 Barrier

Investors need to pay close attention to Ocugen (OCGN) stock based on the movements in the options market lately.

Do Options Traders Know Something About Ocugen (OCGN) Stock We Don't?

Ocugen is a high-risk, high-reward speculative play. The charts for OCGN stock show some promise, but here's the level it has to hold above.

Here's What the Charts Say About Ocugen Stock Now

The WHO could be about to green light a vaccine from one of Ocugen's partners, but that doesn't mean OCGN stock will stay in the green. The post OCGN Stock: Why Ocugen Shares Are Shooting Higher Today appeared first on InvestorPlace.

OCGN Stock: Why Ocugen Shares Are Shooting Higher Today

Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Monday, after Bharat Biotech: a company partner, was given the nod for a COVID-19 vaccine by the World Health Organization. The company saw a large upward movement Monday morning.

Where's Ocugen Stock Headed Monday And Why?

There's both good and bad news for this troubled coronavirus vaccine biotech.

Here's Why Ocugen Is Skyrocketing Today

Ocugen (OCGN) stock is on the move today as traders on social media push the company higher in a new rally for the shares. The post OCGN Stock: What Ocugen Investors Are Saying as Shares Surge Today appeared first on InvestorPlace.

OCGN Stock: What Ocugen Investors Are Saying as Shares Surge Today

The stock price of Ocugen Inc (NASDAQ: OCGN) significantly increased during intraday trading. This is why it happened.

OCGN Stock: Why It Significantly Increased Today

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc . (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in Citi's 16th Annual BioPharma Virtual Conference being held on September 8-10, 2021 and at the H.C. Wainwright Global Investment Conference being held on September 13-15, 2021.

Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences

An investment in Ocugen Inc (NASDAQ: OCGN) one year ago is undoubtedly a sight for sore eyes. Since January 2021, Ocugen stock's year-to-date return has outperformed a number of the world's most popular companies: AMC Entertainment Holdings Inc (NYSE: AMC), Snap Inc (NYSE: SNAP), Apple Inc (NASDAQ: AAPL) and Tesla Inc (NASDAQ: TSLA)

This 28% Short Biotech Company Has A Better 1-Year Return Than AMC, Snap, Apple And Tesla

Vinco Ventures

Support.com

Workhorse Group

SCWorx Corp

Lightning eMotors, Inc

Taking a look at recent short squeeze stocks, there are plenty that could see big declines once Reddit traders cash in their chips. To reduce the risk of heavy losses, steer clear of these seven right now.

7 Short Squeeze Stocks to Sell Before Reddit Traders Cash Out

Ocugen still hopes its Covid-19 vaccine gets approved to start making revenue. OCGN-stock could be worth as much as $9.09 or 19% over today's price assuming its Covid-19 vaccine gets approval.

Ocugen Should Hit $9 If Its Covid-19 Vaccine Gets Approved

It may take time for it to experience its ultimate collapse. But as its still a matter of if rather than when?

Ocugen Stock Will Suffer Its Inevitable Demise Sooner Rather Than Later

OCGN stock is unattractive as regulatory approval delays have limited the revenue and cash flow potential for the Covid-19 vaccine. The post Ocugen Stock Seems Unattractive With Regulatory Uncertainties appeared first on InvestorPlace.

Ocugen Stock Seems Unattractive With Regulatory Uncertainties

OCGN stock is interesting once again as concerns regarding the Delta variant mount. But that should not be your sole reason to invest in Ocugen.

Ocugen Stock Doesn't Have Short-Term Catalysts Needed To Make It a Buy

OCGN stock is a remarkably risky Covid-19 vaccine play, as the company faces a myriad of regulatory roadblocks on different fronts. The post The Odds Are Firmly Against Ocugen Stock Now appeared first on InvestorPlace.

The Odds Are Firmly Against Ocugen Stock Now

The quick FDA approval of Ocugen's Covid-19 vaccine is fading with every passing day. As a result, OCGN stock is down 17% in the past week.

Ocugen's Facing a Major Uphill Climb Without FDA Approval

The company's latest business update sounds all fine and good, but OCGN stock holders want to see some action, not just words. The post Ocugen Stock Is Well-Positioned, But Investors Want Results appeared first on InvestorPlace.

Ocugen Stock Is Well-Positioned, But Investors Want Results

Ocugen's apparent failure to prepare a U.S. trial for Covaxin, which will likely be necessary for FDA approval, bodes badly for OCGN stock. The post Ocugen Stock Still Looks Poised to Tumble appeared first on InvestorPlace.

Ocugen Stock Still Looks Poised to Tumble

In so many words, the story's unchanged with OCGN stock. An all or nothing bet, with more pointing to "nothing," it's still best to stay away.

Ocugen Stock Remains an All or Nothing Wager You Shouldn't Make

Los Angeles, California--(Newsfile Corp. - August 17, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 2, 2021 and June 10, 2021, inclusive (the...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Ocugen, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

New York, New York--(Newsfile Corp. - August 17, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Ocugen, Inc. (NASDAQ: OCGN) alleging that the Company violated federal securities laws.Class Period: February 2, 2021 and June 10, 2021Lead Plaintiff Deadline: August 17, 2021No obligation or cost to you.Learn more about your recoverable losses in OCGN:https://www.kleinstocklaw.com/pslra-1/ocugen-inc-loss-submission-form?id=18611&from=5.

OCGN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 17, 2021 in the Class Action Filed on Behalf of Ocugen, Inc. Limited Shareholders

New York, New York--(Newsfile Corp. - August 16, 2021) -  The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Ocugen, Inc. ("Ocugen") (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania. To get more information go...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Ocugen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 17, 2021 - OCGN

New York, New York--(Newsfile Corp. - August 16, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Ocugen, Inc. (NASDAQ: OCGN) between February 2, 2021 and June 10, 2021, inclusive (the "Class Period"), of the important August 17, 2021 lead plaintiff deadline.SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

Final Deadline Tuesday: Rosen, Leading Investor Counsel, Encourages Ocugen, Inc. Investors with Losses to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - OCGN

News for Ocugen, Inc. Stock (OCGN)